• Type:
  • Category:

BRAIN Biotech AG Deep Dive 2021 | Revolutionizing the Food & Healthcare Industries with CFO



Michael Schneiders, the CFO of BRAIN Biotech AG, presents a summary of the company’s Capital Markets Day highlights on the seat11a platform.


Michael introduces BRAIN Biotech AG as an industrial biotech company with offspring in the pharma and diagnostic.


Michael presents BRAIN Biotech AG’s new corporate structure in three clearly defined business pillars: the enzyme and food ingredient products business BioProducts, custom research services BioScience and the pipeline of breakthrough projects BioIncubator.


Michael shares that the company aims to create a top 10 Global multi-niche food enzyme and ingredient champion. In addition, BRAIN will aim to carve out Akribion Genomics, a genome editing platform, as a subsidiary to attract growth financing.


BRAIN Biotech AG offers critical enabling technology for the Biotransformation of the economy and has potentially discovered an innovative method to deplete cancer cells in oncology treatments.


Michael discusses how Brain Biotech addresses the megatrends of healthier and more sustainable food production. He believes industrialized countries will move increasingly away from livestock farming and find alternative protein sources, which Brain Biotech is happy to help produce through fermentation and precise fermentation.


Brain Biotech is wholly integrated into its value chain, allowing them to produce alternative proteins immaculate, healthy, and reasonable.

Michael shares BRAIN Biotech AG’s ambition to become a top 10 enzyme player globally within five years, doubling their current product revenue from around 40 million to about 80 million.


They are looking for high organic growth in the group and to achieve a 15% (+/- 5PP) group EBITDA margin, 20% for products within five years.

They plan to become a multi-niche player and the partner of choice for their global customer base.


BRAIN Biotech AG already has an international production footprint and plans to expand its production capacity significantly. Finally, Michael talks about Brain Biotech’s yet-to-be-founded subsidiary, Akribion Genomics, and their vision of attracting external growth capital.

Company Profile

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.


The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.


As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.


Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

BRAIN Biotech AG

Darmstaedter Strasse 34-36
64673 Zwingenberg, Germany

phone +49 6251 9331 86


  • Why invest in BRAIN Biotech AG?
  • Future Nutrition will be Produced Differently
  • From Candidates to Industrial Production Processes
  • Merging BRAIN’s Products businesses under the Biocatalysts roof
  • One BioProducts: the big goals
  • Manufacturing footprint
  • Scales of fermentation
  • Growth Initiatives underway
  • Akribion Genomics – Vision and mission
  • Akribion Genomics – Unique Technology Platform
  • Akribion Genomics – A Very Exciting Business Opportunity
  • Efficient & Transparent Organization



Michael Schneiders
CFO | BRAIN Biotech AG​



This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Company Presentations

More Elevator Pitches

Reviews for BRAIN Biotech AG Deep Dive 2021 | Revolutionizing the Food & Healthcare Industries with CFO

There are currently no reviews for BRAIN Biotech AG Deep Dive 2021 | Revolutionizing the Food & Healthcare Industries with CFO
Scroll to top